BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 30683722)

  • 1. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
    Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
    J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Son of Sevenless 1: The pacemaker of KRAS.
    Kessler D; Gerlach D; Kraut N; McConnell DB
    Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
    Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
    J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.
    Burns MC; Howes JE; Sun Q; Little AJ; Camper DV; Abbott JR; Phan J; Lee T; Waterson AG; Rossanese OW; Fesik SW
    Anal Biochem; 2018 May; 548():44-52. PubMed ID: 29444450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange.
    Burns MC; Sun Q; Daniels RN; Camper D; Kennedy JP; Phan J; Olejniczak ET; Lee T; Waterson AG; Rossanese OW; Fesik SW
    Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3401-6. PubMed ID: 24550516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RAS oncogenesis with SOS1 inhibitors.
    Hillig RC; Bader B
    Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles.
    Liao TJ; Jang H; Fushman D; Nussinov R
    Biophys J; 2018 Aug; 115(4):629-641. PubMed ID: 30097175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
    Smith CR; Chen D; Christensen JG; Coulombe R; Féthière J; Gunn RJ; Hollander J; Jones B; Ketcham JM; Khare S; Kuehler J; Lawson JD; Marx MA; Olson P; Pearson KE; Ren C; Tsagris D; Ulaganathan T; Van't Veer I; Wang X; Ivetac A
    J Med Chem; 2024 Jan; 67(1):774-781. PubMed ID: 38156904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
    Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
    J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
    Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
    J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).
    Ilinskaya ON; Singh I; Dudkina E; Ulyanova V; Kayumov A; Barreto G
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1559-67. PubMed ID: 27066977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
    Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
    Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.
    Evelyn CR; Duan X; Biesiada J; Seibel WL; Meller J; Zheng Y
    Chem Biol; 2014 Dec; 21(12):1618-28. PubMed ID: 25455859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods.
    Sarkar D; Olejniczak ET; Phan J; Coker JA; Sai J; Arnold A; Beesetty Y; Waterson AG; Fesik SW
    J Med Chem; 2020 Aug; 63(15):8325-8337. PubMed ID: 32673492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
    Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
    J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
    Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
    Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic studies of H-Ras•GTPγS interactions with nucleotide exchange factor Sos reveal a transient ternary complex formation in solution.
    Vo U; Vajpai N; Embrey KJ; Golovanov AP
    Sci Rep; 2016 Jul; 6():29706. PubMed ID: 27412770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.